Literature DB >> 26918339

Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis.

Xuan Su1, Zhaoqu Li1, Caiyun He2, Weichao Chen1, Xiaoyan Fu1, Ankui Yang1.   

Abstract

BACKGROUND: RET/PTC rearrangements have been identified as a specific genetic event in papillary thyroid cancer (PTC). We conducted this meta-analysis to identify an enriched population who were more likely to occur RET/PTC fusion genes.
METHODS: All relevant studies in the PubMed, Web of Science, and Embase databases were searched up to June 2015. The studies found were screened according to our inclusion and exclusion criteria. All analyses were performed using STATA software.
RESULTS: Eventually, 38 eligible studies comprising 2395 participants were included. Overall analysis indicated that radiation exposure contributed to increased RET/PTC risk (OR = 2.82; 95%CI: 1.38-5.78, P = 0.005). Stratified analysis according to RET/PTC subtype and geographical area showed that this association was restricted to the RET/PTC3 subtype (OR = 8.30, 95%CI: 4.32-15.96, P < 0.001) in the Western population. In addition, age < 18 years, i.e., young age, was associated with higher prevalence of RET/PTC3 (OR = 2.03, 95%CI: 1.14-3.62, P = 0.017), especially in the radiation-exposure subpopulation (OR = 2.35, 95%CI: 1.01-5.49, P = 0.048). The association between female gender and RET/PTC1 risk was more significant in the PTC patients without radiation exposure (OR = 1.69, 95%CI: 1.04-2.74, P = 0.034).
CONCLUSION: Both radiation exposure and young age are associated with increased risk of RET/PTC3 and that female gender is associated with higher prevalence of RET/PTC1 in the subpopulation without radiation exposure. The RET/PTC status in combination with radiation exposure, age, and sex should be considered in the differential diagnosis of suspicious PTC.

Entities:  

Keywords:  RET/PTC; biomarker; papillary thyroid cancer; radiation

Mesh:

Substances:

Year:  2016        PMID: 26918339      PMCID: PMC4941346          DOI: 10.18632/oncotarget.7574

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Rearrangement involving the RET proto-oncogene, referred to RET/PTC (the rearranged during transfection/papillary thyroid carcinoma tyrosine kinase) fusion genes, is one of the best-known mutations in papillary thyroid carcinoma (PTC) [1]. RET/PTC is identified as a specific genetic event in patients with PTC, which forms the basis of differential diagnosis and novel therapeutic approaches to this disease [2]. However, the prevalence rate of the major RET/PTC subtypes in different ethnicities and their correlation with the clinicopathologic features of PTC remains controversial and as yet are not routinely investigated in clinical practice. The receptor tyrosine kinase RET plays a critical role in cell differentiation and proliferation, which is required for normal development of several tissues, especially in early embryogenesis [3]. In 1985, Takahashi and colleagues initially reported RET as a proto-oncogene that can be activated by interchromosomal rearrangement [4]. Subsequent studies demonstrated more than a dozen different forms of RET rearrangement, of which RET/PTC1 and RET/PTC3 are the most common, resulting from the fusion of RET with H4 and of RET with RFG/ELE1 respectively [5]. However, their prevalence rates in PTC exhibit significant geographic variation, ranging from 0% to 86.7% among studies [6, 7]. As risk factors such as sex, age, and radiation exposure are related to PTC pathogenesis, scientists have focused on searching for the factors that increase RET/PTCrearrangement risk. Accordingly, several studies have detected RET/PTC rearrangements more frequently in PTC in children than in adults [8, 9]. A relatively high prevalence of RET/PTC rearrangements was reported in radiation-induced PTC [10]. In addition, ethnicity and demographic characteristics may also influence the frequency of RET/PTC rearrangement [11-13]. To date, numerous relevant studies have been published but with divergent results. In this study, we aimed to identify an enriched population who were more likely to occur RET/PTC1 and RET/PTC3 fusion genes and to provide more useful information on candidate selection for PTC prevention, diagnosis, and treatment. Therefore, we performed this meta-analysis to investigate the association between the presence/absence of RET/PTC1 or RET/PTC3 and radiation exposure, sex, age, and ethnicity.

RESULTS

Basic characteristics of enrolled studies

The article selection flowchart is depicted in Figure 1. A total 2014 records were obtained by searching the PubMed, Web of Science, and Embase databases. After removing duplicates, we found 1206 potentially relevant records. By reviewing titles, abstracts, and full texts according to the inclusion and exclusion criteria, 1168 articles were excluded because they were not relevant, involved in vitro or animal experiments, were reviews or meeting abstracts, contained data covered by other studies, had no raw data, etc. Eventually, 38 full-text articles, which consisted of 2395 PTC cases, met our inclusion criteria and were included in the final meta-analysis [6-10, 14-47].
Figure 1

Flowchart of literature search and selection of studies

The main characteristics of the studies included in this meta-analysis are summarized in Table 1. The status of the RET/PTC fusion gene in the original studies were detected by PCR combined with reverse transcription (RT), Southern Blot or fluorescence in situ hybridization (FISH). The included studies involved populations from different geographical regions, namely Asia, Europe, and America; therefore, we divided the studies into Asian and Western subgroups.
Table 1

Characteristics of studies included in the meta-analysis

First authorYear of publicationEthnicityRegionMethod of detectionRadiationNo.of patients
Nikiforov et al1997Belarussian, Los Angeles, CincinnatiWesternRT-PCRMixed55
Bounacer et al1997FrenchWesternRT-PCRMixed39
Motomura et al1998JapaneseAsianRT-PCRNon-radiation21
Smida et al1999Belarussian, GermanWesternRT-PCRMixed83
Rabes et al2000Belarus, Russia, UkrainianWesternPCRRadiation191
Elisei et al2001Belarus, ItaianWesternPCRMixed89
Puxeddu et al2003ItalianWesternRT-PCR, Southern BlotNon-radiation48
Rhoden et al2004AmericanWesternRT-PCRNM25
Nakazawa et al2005JapaneseAsianRT-PCRNon-radiation169
Brzezianska et al2006PolishWesternRT-PCRNM33
Hamatani et al2008JapaneseAsianRT-PCRMixed71
Tuttle et al2008RussianWesternRT-PCRRadiation76
Lam et al2002China, Hong KongAsianRT-PCRNon-radiation21
Detours et al2005UkrainianWesternRT-PCRMixed20
Lima et al2004UkrainianWesternRT-PCRMixed34
Penko et al2005AmericanWesternPCRMixed13
Romei et al2008ItalianWesternRT-PCRNon-radiation70
Hieber et al2011UkrainianWesternFISHRadiation22
Guerra et al2014ItalianWesternRT-PCRNM72
Zou et al2014Saudi ArabianAsianRT-PCRNM88
Chung et al1999KoreanAsianRT-PCRNon-radiation31
Powell et al2005UkrainianWesternPCRMixed35
Unger et al2004UkrainianWesternFISHRadiation29
Wang et al2008ChineseAsianRT-PCRNon-radiation126
Nikiforova et al2004Belorussian, UkrainianWesternPCRMixed137
Basolo et al2002ItalianWesternRT-PCRNM91
Rao et al2014IndianAsianRT-PCRNon-radiation30
Collins et al2002AmericanWesternIHCMixed64
Chung et al2004KoreanAsianRT-PCR+IHCNon-radiation22
Unger et al2006UkrainianWesternFISHRadiation13
Sadetzki et al2004IsraelisAsianRT-PCRMixed49
Smyth et al2005IrishWesternTaqmanNM34
Learoyd et al1998Australian, SwedishWesternRT-PCRMixed50
Nakazawa et al2009JapaneseAsianFISH+RT-PCRNon-radiation14
Di Cristofaro et al2005Ukrainian, FrenchWesternRT-PCRMixed50
Erdogan2008TurkishAsianRT-PCRNon-radiation101
Fenton et al2000AmericanWesternPCRNon-radiation33
Guerra et al2011ItalianWesternRT-PCRNM50
Stanojevic et al2011SerbianWesternPCRNon-radiation266
We also summarized the positive rates of RET/PTC from each original study (Table 2). The overall prevalence of RET/PTC was relatively higher in the Western populations (42.19%) than in the Asian populations (36.73%). A similar tendency was observed for the RET/PTC1 subtype, whereas the Asian populations demonstrated a higher positive rate for the RET/PTC3 subtype (Asian vs. Western populations: 26.50% vs. 17.05%). In the Asian studies, the positive rates of RET/PTC3 in the studies by Lam et al. [16] and Rao et al. [7] were up to 85.71% and 86.67%, respectively, while another six studies reported a much lower incidence of RET/PTC3 that ranged from 0% to 20.79% [9, 14, 20-23].
Table 2

Positive rates of RET/PTC1 and RET/PTC3 in each original study

First authorYear of publicationNo. of PTC casesFreq. of RET/PTC1 and 3RET/PTC1 and 3(%)Freq. of RET/PTC1RET/PTC1(%)Freq. of RET/PTC3RET/PTC3(%)
For Asian studies 36.73%21.06%26.50%
Motomura et al199821733.33%523.81%29.52%
Nakazawa et al20051694828.40%4325.44%84.73%
Hamatani et al2008711216.90%
Lam et al2002211885.71%1885.71%
Zou et al2014881213.64%1213.64%
Chung et al199931412.90%
Wang et al20081261814.29%
Rao et al2014302686.67%00.00%2686.67%
Chung et al20042229.09%14.55%14.55%
Sadetzki et al2004492244.90%2040.82%00.00%
Nakazawa et al200914428.57%428.57%00.00%
Erdogan20081016766.34%3231.68%2120.79%
For Western studies42.19%25.25%17.05%
Nikiforov et al1997554072.73%1425.45%2545.45%
Bounacer et al1997391846.15%1538.46%512.82%
Smida et al1999833946.99%2631.33%1315.66%
Rabes et al20001918645.03%4825.13%3819.90%
Elisei et al2001894044.94%1820.22%2629.21%
Puxeddu et al2003481327.08%816.67%510.42%
Rhoden et al2004251872.00%1872.00%520.00%
Brzezianska et al200633721.21%
Tuttle et al2008761317.11%1114.47%56.58%
Detours et al200520735.00%15.00%210.00%
Lima et al2004341441.18%
Penko et al200513753.85%538.46%215.38%
Romei et al20081318.57%1217.14%
Hieber et al2011221777.27%
Guerra et al2014721216.67%
Powell et al2005351645.71%
Unger et al200429517.24%26.90%310.34%
Nikiforova et al20041374835.04%1611.68%3223.36%
Basolo et al2002912830.77%66.59%2224.18%
Collins et al2002644468.75%
Unger et al2006131076.92%
Smyth et al2005341338.24%1029.41%38.82%
Learoyd et al19985048.00%48.00%00.00%
Di Cristofaro et al2005503060.00%2652.00%1326.00%
Fenton et al2000331442.42%1133.33%39.09%
Guerra et al2011501836.00%
Stanojevic et al20112665520.68%4215.79%134.89%

Association between radiation exposure and RET/PTC fusion genes

As radiation exposure is the best-known risk factor for PTC, we initially investigated the effect of radiation on RET/PTC rearrangement (Table 3). Fourteen studies investigated the distribution difference of radiation exposure between RET/PTC-positive and -negative patients with PTC. When the RET/PTC1 and RET/PTC3 subtypes were combined, radiation exposure conferred increased overall risk for RET/PTC development (OR = 2.82, 95%CI: 1.38–5.78; P = 0.005, Figure 2) and there was moderate heterogeneity (I2 = 74%, Phet < 0.001). Stratified analysis according to geographical region decreased the heterogeneity slightly, and increased risk for RET/PTC rearrangement persisted in the Western subpopulation, demonstrating an increased OR of 3.97 (95%CI: 2.03–7.75; P < 0.001).
Table 3

Meta-analysis results for association between RET/PTC fusion genes and radiation exposure in patients with PTC

Radiation exposure vs. non-radiation exposureNo. of studiesNo. of cases/controlsOR(95%CI)P valueModelI2Pheta
For RET/PTC1 and 3
 All14537/3882.82(1.38,5.78)0.005Random74%<0.001
 Region
 Asian4232/710.88(0.26,2.93)0.833Random56%0.077
 Western10305/3173.97(2.03,7.75)<0.001Random59%<0.001
For RET/PTC1
 All9285/2871.86(0.66, 5.28)0.243Random76.00%<0.001
 Region
 Asian137/120.24(0.06,0.96)0.043Random//
 Western8248/2752.46(0.83,7.27)0.104Random74.10%<0.001
For RET/PTC3
 Allb8243/2408.30(4.32,15.96)<0.001Fixed0.00%0.980
 Region
 Asian///////
 Western8243/2408.30(4.32,15.96)<0.001Fixed0.00%0.980

P-value for heterogeneity test;

Data from Sadetzki et al. [21] and Learoyd et al. [6] showed that the RET/PTC3 gene prevalence was 100% in both the groups with and without radiation exposure and that the OR and standard error could not be estimated; therefore, these studies were excluded. The statistically significant results are highlighted in bold.

Figure 2

Results of the association between RET/PTC1 and RET/PTC3 fusion genes and radiation exposure in patients with PTC

P-value for heterogeneity test; Data from Sadetzki et al. [21] and Learoyd et al. [6] showed that the RET/PTC3 gene prevalence was 100% in both the groups with and without radiation exposure and that the OR and standard error could not be estimated; therefore, these studies were excluded. The statistically significant results are highlighted in bold. When the RET/PTC1 and RET/PTC3 subtypes were considered separately, radiation exposure conferred significantly higher risk for RET/PTC3 rearrangement (OR = 8.30, 95%CI: 4.32–15.96; P < 0.001, Figure 3) but not for RET/PTC1 rearrangement. This association was only evident in the Western subpopulation. Separate pooled analysis for the RET/PTC1 and RET/PTC3 subtypes was not performed for the Asian subpopulation because three original studies involving this population investigated the combined status of RET/PTC1 and RET/PTC3, and the data could not be extracted separately [9, 15, 22]. Only one study with a small sample in an Asian country reported the RET/PTC1 and RET/PTC3 fusion gene data separately [21]. There was significant inter-study heterogeneity in the RET/PTC1 analysis but not in the RET/PTC3 analysis.
Figure 3

Results of the association between RET/PTC3 fusion gene and radiation exposure in patients with PTC

Association between RET/PTC fusion genes and age

Different age effects have been observed in the development of PTC, and we therefore explored whether young age affected the penetrance of theRET/PTC fusion genes in children and adolescents (Table 4). In this meta-analysis, age < 18 years was considered young, i.e., children and adolescents. In the combined analysis of the RET/PTC1 and RET/PTC3 subtypes, no association was observed between age and RET/PTC rearrangement. In the separate analysis of the RET/PTC1 and RET/PTC3 subtypes, young people had nearly two-fold greater risk for RET/PTC3 rearrangement (Figure 4) but penetrance of the RET/PTC1 fusion gene was not affected. When radiation exposure was also considered, young people in the subpopulation with radiation exposure had higher risk for developing RET/PTC3 rearrangement as compared to adults with radiation exposure. These positive associations were performed in a fixed-effects model and had slight inter-study heterogeneity (all Phet > 0.10).
Table 4

Meta-analysis results for association between RET/PTC fusion genes and age in patients with PTC

Young people vs. adultNo. of studiesNo. of cases/controlsOR(95%CI)P valueModelI2Pheta
For RET/PTC1 and 3
 All8187/3321.10(0.56,2.16)0.783Random51.50%0.044
 Region
 Asian241/1491.76(0.84,3.69)0.133Fixed4.30%0.307
 Western6146/1830.98(0.41,2.31)0.956Random54.50%0.052
 Radiation
 Radiation exposure6116/1220.88(0.48,1.62)0.682Fixed41.50%0.129
 Non-radiation exposure571/2001.46(0.81,2.65)0.212Fixed33.90%0.195
For RET/PTC1
 All6172/2860.98(0.60,1.58)0.921Fixed7.20%0.370
 Region
 Asian241/1491.33(0.61,2.91)0.476Fixed0.00%0.466
 Western4131/1370.81(0.44,1.50)0.507Fixed21.40%0.282
 Radiation
 Radiation exposure5107/1090.52(0.26,1.05)0.070Fixed49.30%0.096
 Non-radiation exposure571/2001.47(0.76,2.86)0.250Fixed0.00%0.574
For RET/PTC3
 All7179/3182.03(1.14,3.62)0.017Fixed46.70%0.081
 Region
 Asian242/1483.23(0.87,12.00)0.080Fixed7.20%0.299
 Western5137/1701.84(0.97,3.50)0.206Random50.1%%0.091
 Radiation
 Radiation exposure5107/1092.35(1.01,5.49)0.048Fixed0.00%0.574
 Non-radiation exposure572/1991.68(0.28,10.01)0.570Random67.00%0.028

P-value for heterogeneity test. The statistically significant results are highlighted in bold.

Figure 4

Results of the association between RET/PTC3 fusion gene and young age in patients with PTC

P-value for heterogeneity test. The statistically significant results are highlighted in bold.

Association between RET/PTC fusion genes and sex

Females are more likely to develop PTC, therefore we investigated whether female gender increases the chance of RET/PTC rearrangement in patients with PTC. As suggested by the findings in Table 5, sex was not statistically associated with RET/PTC status in the combined analysis. In subgroup analysis, a pooled analysis of 13 studies showed that female gender was associated with RET/PTC1 development in the subpopulation without radiation exposure. Female patients had 1.69-fold greater risk for RET/PTC1 rearrangement than male patients did (95%CI: 1.04–2.74; P = 0.034, Figure 5). However, female gender did not appear to play a role in RET/PTC3 rearrangement (all, P > 0.05). Only slight inter-study heterogeneity was observed in all of the above analyses (all Phet > 0.10).
Table 5

Meta-analysis results for association between RET/PTC fusion genes and sex in patients with PTC

Female vs. maleNo. of studiesNo. of cases/controlsOR(95%CI)P valueModelI2Pheta
For RET/PTC1 and 3
  All271211/4741.04(0.81,1.33)0.775Fixed0.00%0.938
  Region
  Asian9373/1381.42(0.81,2.49)0.216Fixed0.00%0.754
  Western18838/3360.95(0.72,1.27)0.747Fixed0.00%0.934
  Radiation
  Radiation exposure11369/1740.94(0.63,1.41)0.760Fixed0.00%0.941
  Non-radiation exposure17721/2581.28(0.90,1.82)0.171Fixed7.20%0.370
For RET/PTC1
  All a16832/3241.21(0.87,1.69)0.256Fixed0.00%0.857
  Region
  Asian5213/620.98(0.48,2.01)0.962Fixed0.00%0.604
  Western11619/2611.28(0.88,1.87)0.193Fixed0.00%0.796
  Radiation
  Radiation exposure4185/1041.22(0.70,2.11)0.482Fixed0.00%0.892
  Non-radiation exposure13581/1921.69(1.04,2.74)0.034Fixed0.00%0.768
For RET/PTC3
  All,b17785/3040.87(0.60,1.27)0.466Fixed0.00%0.625
  Region
  Asian5155/401.54(0.59,3.99)0.378Fixed0.00%0.763
  Western11619/2610.77(0.51,1.17)0.223Fixed0.00%0.527
  Radiation
  Radiation exposure4185/1040.82(0.45,1.48)0.504Fixed0.00%0.903
  Non-radiation exposure11570/1861.06(0.60,1.87)0.847Fixed0.00%0.696

P-value for heterogeneity test;

Data from Rao et al. [7] and Detours et al. [31] showed that RET/PTC1 gene prevalence was 100% in both female and male groups and that the OR and standard error could not be estimated; therefore, these studies were excluded. The statistically significant results are highlighted in bold.

Figure 5

Results of the association between RET/PTC1 fusion gene and female gender in PTC patients without radiation exposure

P-value for heterogeneity test; Data from Rao et al. [7] and Detours et al. [31] showed that RET/PTC1 gene prevalence was 100% in both female and male groups and that the OR and standard error could not be estimated; therefore, these studies were excluded. The statistically significant results are highlighted in bold.

Heterogeneity testing and sensitivity analysis

The inter-study heterogeneities in each comparison are presented in Tables 3–5. Pooled analyses for assessing the effect of radiation exposure and young age on the combined status of the RET/PTC1 and RET/PTC3 fusion genes demonstrated moderate heterogeneity. To explore the source of heterogeneity, subgroup analyses based on ethnicity and RET/PTC subtype were performed. Heterogeneity was decreased in the subgroup analysis and may be partly explained by the different ethnicities and RET/PTC subtypes (Tables 3 and 5). Sensitivity analysis was also conducted to assess the influence of individual studies on the overall risk of RET/PTC rearrangement by excluding any single study in turn and recalculating the pooled ORs and 95%CI. For the effect of radiation on RET/PTC rearrangement, Sadetzki et al. [21], Nakazawa et al. [22], and Bounacer et al. [24] reported greater differences in the risk estimates compared with other studies in the sensitivity analysis. Sensitivity analysis excluding the three studies generated a similar pooled OR of 3.30 (95%CI: 1.96–5.54, P < 0.001; I2= 32.1%, Phet = 0.142) among homogeneous studies. For the effect of young age on RET/PTC rearrangement, the outlier studies appeared to be the studies of Smida et al. (1999)[8] and Hieber et al. (2011)[35]. After removing the two studies, the heterogeneity was no longer significant (I2= 34.0%, Phet = 0.181), and similar estimates (OR = 1.10 vs. 1.53) were generated before and after these data were removed, indicating the relatively high stability of the results.

Publication bias

Begg's test and Egger's test were performed to quantitatively evaluate the publication bias of the studies; the results are listed in Table 6. No significant publication bias was observed in all comparisons (all, P > 0.10).
Table 6

Analysis for publication bias

VariableBegg's testEgger's test
z valueP valueat valueP valuea
For RET/PTC1 and 3
  Radiation exposure vs. non-radiation exposure0.930.3521.340.205
  Female vs. male1.020.3070.240.811
  Children and adolecent vs. adult−0.250.8050.160.882
For RET/PTC1
  Radiation exposure vs. non-radiation exposure1.250.2111.710.132
  Female vs. male0.270.7870.150.879
  Children and adolecent vs. adult−0.190.8510.390.715
For RET/PTC3
  Radiation exposure vs. non-radiation exposure−0.560.573−1.750.156
  Female vs. male0.270.7870.590.567
  Children and adolecent vs. adult0.450.6521.920.113

P value>0.1 was considered as no publication bias.

P value>0.1 was considered as no publication bias.

DISCUSSION

Previous study results on the relationship between PTC-related risk factors and RET/PTC rearrangement were controversial. To our knowledge, this is the first meta-analysis evaluating the effect of radiation exposure, female gender, and young age on RET/PTC rearrangement. By performing the present meta-analysis, we found that radiation exposure contributed to increased risk of RET/PTC rearrangement, especially for the RET/PTC3 subtype. Young age was also associated with higher prevalence of RET/PTC3, and this association was more significant in the subpopulation exposed to radiation. Our pooled estimate also demonstrated an association between female gender and higher prevalence of the RET/PTC1 subtype in the subpopulation that had not been exposed to radiation. These results identify an enriched population of RET/PTC fusion genes in patients with PTC and provide novel insights into the utility of RET/PTC rearrangement in the differential diagnosis of suspicious PTC. Exposure to ionizing radiation is a well-known risk factor for thyroid cancer, particularly for papillary carcinoma [48, 49]. Therefore, it is likely that radiation exposure may also be a causative factor for RET/PTC rearrangement. Our pooled estimates provide clear evidence that radiation exposure could be responsible for the difference in RET/PTC3 prevalence between sporadic and radiation-associated tumors, whereas the rate of RET/PTC1 prevalence was similar between the two groups. The corresponding pooled OR for RET/PTC3 was up to 8.30, and this association was evident in the Western populations. However, we could not derive a negative or null association in the Asian population because of a lack of original studies from the Asian region. There are valid reasons to believe that there is a causative link between radiation exposure and RET/PTC rearrangements. For example, Nikiforov et al. reported much higher RET/PTC3 prevalence in post-Chernobyl PTC than in subjects without radiation exposure [10]. In addition, RET/PTC rearrangement, predominantly RET/PTC3, in thyroid cells, can be induced by ionizing radiation [50]. This may be linked to the particular effectiveness of radiation in causing double-strand breaks, which would be the direct cause of RET rearrangement [50, 51]. This mechanism may partially explain the association between radiation exposure and RET/PTC rearrangement in thyroid cancer. The data synthesis in the present meta-analysis also demonstrated increased risk of RET/PTC3 in PTC in young people. Our observations further indicate that young patients who exposed to radiation have higher RET/PTC3 risk than young patients who have not been exposed to radiation. Original studies have shown that RET/PTC3 is more common in children and adolescents compared to adults [8, 9]. When the radiation exposure effect was considered in young people, RET/PTC3 was indicated as the most common form of rearrangement in radiation-associated childhood PTC [8, 10, 25, 52]. As the thyroid is very sensitive to radiation, the thyroid of young people might be more vulnerable to radiation than that of adults, which may result in higher RET/PTC prevalence in young people [53]. Nevertheless, it is important to consider that the statistical power in each original study may be partly determined by the cutoff value of age, such as age at diagnosis and age at exposure to radiation. When the cutoff age varies, the issue of the impact of patient age on RET/PTC rearrangement remains inconclusive, which would require further validation. By setting a cutoff age of 18 years in this meta-analysis, the corresponding results may indicate the relatively low defense ability of children against pathogenic factors. Concerning the impact of sex, we observed that the association between female gender and increased RET/PTC1 risk was more significant in patients who had not been exposed to radiation. For unknown reasons, thyroid cancer is three times more prevalent in women than in men [54]. One possible explanation for this gender disparity is the hormonal differences between men and women. It has been documented that chromosome breaks and sister chromatid exchanges are elevated in women who are pregnant or taking oral contraceptives [55]. There is also evidence supporting the premise that RET/PTC is an estrogen-dependent gene required for breast cancer cell growth [56]. The above evidence suggests that some inherent differences render females more susceptible to RET rearrangements. Nevertheless, this study has some limitations. First, although we included all available relevant articles in this meta-analysis, the sample sizes remain insufficiently large. Second, most studies in relation to the association between radiation exposure and RET/PTC3 were from the Western countries, thus the generalizability of our conclusions is limited. In the future, more studies are needed to confirm this association in Asian regions. Third, only two common RET/PTC subtypes, RET/PTC1 and RET/PTC3, were considered in this study, mainly due to the limitation of current laboratory techniques for simultaneously detecting all RET/PTC subtypes. In conclusion, both radiation exposure and young age, i.e., age < 18 years, are associated with increased risk of RET/PTC3 rearrangement. In addition, female gender is associated with higher prevalence of the RET/PTC1 subtype in the subpopulation not exposed to radiation. We suggest that RET/PTC status in combination with radiation exposure, age, and sex should be considered when differential diagnoses are suggested for suspicious patients. Further large-scale studies concerning the relationship between radiation exposure and RET/PTC in the Asian population are required to confirm our meta-analysis results.

MATERIALS AND METHODS

Search strategy

We searched the PubMed, Web of Science, and Embase databases for all articles on the association between the RET/PTC fusion gene and PTC up to June 2015. The published date of available articles in this study was from 1959 to 2015. The keywords used for the search were “RET/PTC”, “RET/PTC fusion gene”, or “RET/PTC fusion oncoproteins” in combination with “Thyroid Cancer”, “Thyroid Carcinoma”, “Thyroid Neoplasms”, or “Thyroid Papillary Carcinoma”. The references of the articles acquired were also searched manually to broaden the search. When there was overlapping data, only the largest and most recent study was selected for this meta-analysis. If the data presented in an article were unclear, we contacted the author for specific raw data.

Inclusion and exclusion criteria

Eligible studies had to meet the following criteria: (1) the association between the RET/PTC fusion gene and the clinicopathological features of patients with PTC was explored; (2) PTC diagnosis was made according to the pathology results; (3) studies were full-text articles; and (4) there was sufficient data for estimating an odds ratio (OR) with a 95% confidence interval (CI). The exclusion criteria were: (1) duplicate publication; (2) article was an abstract, comment, review, conference proceeding, or editorial; (3) insufficient data were reported; and (4) study was not in English or Chinese.

Data extraction

The following items were collected: first name of first author; year of publication; population of study; number of enrolled patients; frequency of RET/PTC fusion gene; detection method; whether study subjects were children or adults; and clinicopathological features (sex, age, radiation history, and ethnicity). The above information was carefully extracted by two independent investigators (Xuan Su and Zhaoqu Li). If the two investigators could not reach a consensus, the result was reviewed by a third investigator (Caiyun He).

Statistical analyses

The strength of the association between RET/PTC and radiation exposure, age, and sex was estimated by OR and 95%CI. Two-sided P-values were evaluated in this meta-analysis, and P < 0.05 was considered statistically significant. The chi-square–based Q test and I2 statistic were used to assess the statistical heterogeneity among studies. For the Q statistic, P < 0.10 was considered statistically significant for heterogeneity. When there was heterogeneity, a random-effects model based on the DerSimonian and Laird method was used to calculate the pooled OR of each study [57]; otherwise, a fixed-effects model based on the Mantel–Haenszel method was used [58]. Publication bias was examined using Begg's and Egger's tests [59, 60], where P < 0.10 was considered statistically significant. All analyses were performed using STATA 12.0. All tests were two-sided and the significance level was set at 0.05.
  60 in total

1.  Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.

Authors:  Y E Nikiforov; J M Rowland; K E Bove; H Monforte-Munoz; J A Fagin
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

2.  Activation of a novel human transforming gene, ret, by DNA rearrangement.

Authors:  M Takahashi; J Ritz; G M Cooper
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

Review 3.  The changing epidemiology of thyroid cancer: why is incidence increasing?

Authors:  Riccardo Vigneri; Pasqualino Malandrino; Paolo Vigneri
Journal:  Curr Opin Oncol       Date:  2015-01       Impact factor: 3.645

4.  RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan).

Authors:  Tadao Nakazawa; Tetsuo Kondo; Yoshihiko Kobayashi; Noboru Takamura; Shin-ichi Murata; Kaori Kameyama; Akira Muramatsu; Kohichi Ito; Makio Kobayashi; Ryohei Katoh
Journal:  Cancer       Date:  2005-09-01       Impact factor: 6.860

Review 5.  Genetic basis and gene therapy trials for thyroid cancer.

Authors:  Hussam Al-Humadi; Apostolos Zarros; Rafal Al-Saigh; Charis Liapi
Journal:  Cancer Genomics Proteomics       Date:  2010 Jan-Feb       Impact factor: 4.069

Review 6.  Thyroid cancer gender disparity.

Authors:  Reza Rahbari; Lisa Zhang; Electron Kebebew
Journal:  Future Oncol       Date:  2010-11       Impact factor: 3.404

7.  Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas.

Authors:  Kristian Unger; Horst Zitzelsberger; Giuliana Salvatore; Massimo Santoro; Tatjana Bogdanova; Herbert Braselmann; Peter Kastner; Lyudmilla Zurnadzhy; Nikolay Tronko; Peter Hutzler; Gerry Thomas
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

8.  Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population.

Authors:  Ewa Brzeziańska; Małgorzata Karbownik; Monika Migdalska-Sek; Dorota Pastuszak-Lewandoska; Jan Włoch; Andrzej Lewiński
Journal:  Mutat Res       Date:  2006-02-17       Impact factor: 2.433

9.  RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.

Authors:  Kiyohiro Hamatani; Hidetaka Eguchi; Reiko Ito; Mayumi Mukai; Keiko Takahashi; Masataka Taga; Kazue Imai; John Cologne; Midori Soda; Koji Arihiro; Megumu Fujihara; Kuniko Abe; Tomayoshi Hayashi; Masahiro Nakashima; Ichiro Sekine; Wataru Yasui; Yuzo Hayashi; Kei Nakachi
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

10.  ret rearrangements in Japanese pediatric and adult papillary thyroid cancers.

Authors:  T Motomura; Y E Nikiforov; H Namba; K Ashizawa; S Nagataki; S Yamashita; J A Fagin
Journal:  Thyroid       Date:  1998-06       Impact factor: 6.568

View more
  19 in total

Review 1.  Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.

Authors:  Timothy M Ullmann; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey
Journal:  Gland Surg       Date:  2018-10

2.  MRI guided needle localization in a patient with recurrence pleomorphic sarcoma and post-operative scarring.

Authors:  Ching-Di Chang; Jesse Wei; Jeffrey D Goldsmith; Mark C Gebhardt; Jim S Wu
Journal:  Skeletal Radiol       Date:  2017-03-09       Impact factor: 2.199

3.  RET/PTC Gene Rearrangements in Thyroid Carcinogenesis: Assessment and Clinico-Pathological Correlations.

Authors:  Mosin S Khan; Qurteeba Qadri; Mudasir J Makhdoomi; Muneer A Wani; Aejaz A Malik; Madiha Niyaz; Shariq R Masoodi; Khurshid I Andrabi; Rauf Ahmad; Syed Mudassar
Journal:  Pathol Oncol Res       Date:  2018-11-22       Impact factor: 3.201

Review 4.  RET kinase inhibitors for RET-altered thyroid cancers.

Authors:  Danica M Vodopivec; Mimi I Hu
Journal:  Ther Adv Med Oncol       Date:  2022-06-21       Impact factor: 5.485

5.  Integration of a radiation biomarker into modeling of thyroid carcinogenesis and post-Chernobyl risk assessment.

Authors:  Jan Christian Kaiser; Reinhard Meckbach; Markus Eidemüller; Martin Selmansberger; Kristian Unger; Viktor Shpak; Maria Blettner; Horst Zitzelsberger; Peter Jacob
Journal:  Carcinogenesis       Date:  2016-10-11       Impact factor: 4.944

6.  Associations between RET tagSNPs and their haplotypes and susceptibility, clinical severity, and thyroid function in patients with differentiated thyroid cancer.

Authors:  Caiyun He; Jiangjun Ma; Yongle Jiang; Xuan Su; Xiao Zhang; Weichao Chen; Zulu Ye; Tiancheng Deng; Wenze Deng; Ankui Yang
Journal:  PLoS One       Date:  2017-11-13       Impact factor: 3.240

7.  Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese population.

Authors:  Rui Liu; Lifeng Ning; Xiaoli Liu; Huiping Zhang; Yaqin Yu; Shangchao Zhang; Wenwang Rao; Jieping Shi; Hui Sun; Qiong Yu
Journal:  Oncotarget       Date:  2017-02-28

8.  Nationwide cohort study on the epidemiology and survival outcomes of thyroid cancer.

Authors:  Fu-Chao Liu; Huan-Tang Lin; Shu-Fu Lin; Chang-Fu Kuo; Ting-Ting Chung; Huang-Ping Yu
Journal:  Oncotarget       Date:  2017-07-22

9.  Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma.

Authors:  Lihua Huang; Xuming Wang; Xuan Huang; Huawei Gui; Yan Li; Qiongxia Chen; Dongling Liu; Lijiang Liu
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

10.  RhoGAP domain-containing fusions and PPAPDC1A fusions are recurrent and prognostic in diffuse gastric cancer.

Authors:  Hanna Yang; Dongwan Hong; Soo Young Cho; Young Soo Park; Woo Ri Ko; Ju Hee Kim; Hoon Hur; Jongkeun Lee; Su-Jin Kim; Sun Young Kwon; Jae-Hyuk Lee; Do Youn Park; Kyu Sang Song; Heekyung Chang; Min-Hee Ryu; Kye Soo Cho; Jeong Won Kang; Myeong-Cherl Kook; Nina Thiessen; An He; Andy Mungall; Sang-Uk Han; Hark Kyun Kim
Journal:  Nat Commun       Date:  2018-10-25       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.